HGEN - CytoDyn And Humanigen: Ticking Time Bombs Impending Results Likely To Fail
- CytoDyn and Humanigen are running high-visibility trials focused on ameliorating COVID-19 acute inflammation.
- Acute inflammation plays a major role in the hospitalizations and deaths of patients with COVID-19.
- Despite monoclonal antibody drug approvals for 88 chronic inflammatory indications, warranted FDA approvals of monoclonal antibodies targeting acute inflammatory indications are almost non-existent, even though many have been tried.
- It is reckless to invest in pre-commercial companies operating "priority programs" using monoclonal antibodies to fight COVID-19 acute inflammation.
For further details see:
CytoDyn And Humanigen: Ticking Time Bombs, Impending Results Likely To Fail